



# Quoi de neuf en anesthésie obstétricale ?

**Lionel Bouvet**

Hospices Civils de Lyon

Hôpital Femme Mère Enfant

Lyon



**Aucun conflit d'intérêt**

# Practice Guidelines for Obstetric Anesthesia

*An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology\**

*Anesthesiology 2016; 124:270-300*

- Recommendations ASA / SOAP
- Pas de changement notable vs. 2007
- Actualisation des données bibliographiques

Recommandations professionnelles:

## **Organisation de l'Anesthésie-Réanimation Obstétricale.**

**SFAR**

Société Française d'Anesthésie et de Réanimation

**Sociétés ou groupements professionnels associés : CARO, CNGOF, CNSF, IADE, SFN**

Club d'Anesthésie-Réanimation en Obstétrique

Recommandations portant sur les **moyens matériels et humains**,  
l'organisation du **parcours de soins**, l'établissement de **procédures**,  
nécessité de **formation et évaluation (protocoles, RMM, EPP, réseaux)**  
Intègre des dispositions légales  
**Appropriation de ces recommandations, intégration dans la charte de  
fonctionnement avec comme objectif la réduction de la morbidité  
maternelle**

# Intubation

# Failed tracheal intubation during obstetric general anaesthesia: a literature review

International Journal of Obstetric Anesthesia (2015) 24, 356–374

S.M. Kinsella,<sup>a</sup> A.L. Winton,<sup>a</sup> M.C. Mushambi,<sup>b</sup> K. Ramaswamy,<sup>c</sup> H. Swales,<sup>d</sup>  
A.C. Quinn,<sup>e</sup> M. Popat<sup>f</sup>

**Période 1970 – 2015, 33 publications, 142 560 femmes**

**Échec intubation : 1/390 AG obstétricale (2,6 /1000 anesthésies)**

**Décès consécutif : 1/90 échecs**

**Recours à la cricothyroïdotomie : 1/60 échecs (3,4/100 000)**

**Recours au masque laryngé**


## Guidelines

Obstetric Anaesthetists' Association and Difficult Airway Society  
guidelines for the management of difficult and failed tracheal  
intubation in obstetrics\*

M. C. Mushambi,<sup>1</sup> S. M. Kinsella,<sup>2</sup> M. Popat,<sup>3</sup> H. Swales,<sup>4</sup> K. K. Ramaswamy,<sup>5</sup> A. L. Winton<sup>6</sup> and  
A. C. Quinn<sup>7,8</sup>



# Master algorithm – obstetric general anaesthesia and failed tracheal intubation



# Master algorithm – obstetric general anaesthesia and failed tracheal intubation

## Algorithm 1 Safe obstetric general anaesthesia

Pre-induction planning and preparation  
Team discussion

Anticiper l'échec de l'intubation avant l'induction  
Évaluer accès VA : IOT, ventilation masque, cricothyroïdectomie (écho)  
Ventilation au masque facial avec  $P < 20 \text{ cmH}_2\text{O}$   
Vidéolaryngoscope  
Pas plus de 3 tentatives d'IOT

Fail

## Algorithm 2 Obstetric failed tracheal intubation

Ventilation au masque facial pour oxygéner  
Masque laryngé (2<sup>e</sup> génération) si césarienne impérative  
Maximum 2 tentatives masque laryngé

Fail

Success

Is it essential/safe  
to proceed with surgery  
immediately?

## Algorithm 3 Can't intubate, can't oxygenate

Cricothyroïdectomie  
Échographie cervicale  
Réévaluation du caractère impératif de la césarienne

Proceed with surgery



## Table 1 – proceed with surgery?

Factors to consider	WAKE	←—————→	—————→	PROCEED	
Before induction	Maternal condition	• No compromise	• Mild acute compromise	• Haemorrhage responsive to resuscitation	• Hypovolaemia requiring corrective surgery • Critical cardiac or respiratory compromise, cardiac arrest
	Fetal condition	• No compromise	• Compromise corrected with intrauterine resuscitation, pH < 7.2 but > 7.15	• Continuing fetal heart rate abnormality despite intrauterine resuscitation, pH < 7.15	• Sustained bradycardia • Fetal haemorrhage • Suspected uterine rupture
	Anaesthetist	• Novice	• Junior trainee	• Senior trainee	• Consultant/specialist
	Obesity	• Supernormal	• Morbid	• Obese	• Normal
	Surgical factors	• Complex surgery or major haemorrhage anticipated	• Multiple uterine scars • Some surgical difficulties expected	• Single uterine scar	• No risk factors
	Aspiration risk	• Recent food	• No recent food • In labour • Opioids given • Antacids not given	• No recent food • In labour • Opioids not given • Antacids given	• Fasted • Not in labour • Antacids given
	Alternative anaesthesia • regional • securing airway awake	• No anticipated difficulty	• Predicted difficulty	• Relatively contraindicated	• Absolutely contraindicated or has failed • Surgery started
After failed intubation	Airway device/ventilation	• Difficult facemask ventilation • Front-of-neck	• Adequate facemask ventilation	• First generation supraglottic airway device	• Second generation supraglottic airway device
	Airway hazards	• Laryngeal oedema • Stridor	• Bleeding • Trauma	• Secretions	• None evident

Anticiper l'échec de l'intubation avant l'induction



**Césarienne**

# Randomized Double-blinded Comparison of Norepinephrine and Phenylephrine for Maintenance of Blood Pressure during Spinal Anesthesia for Cesarean Delivery

Warwick D. Ngan Kee, M.B.Ch.B., M.D., F.A.N.Z.C.A., F.H.K.A.M.,  
Shara W. Y. Lee, B.Sc.(Hons.), M.Sc., Ph.D., Floria F. Ng, R.N., B.A.Sc.,  
Perpetua E. Tan, B.Sc., M.Phil., Kim S. Khaw, M.B.B.S., M.D., F.R.C.A., F.H.K.A.M.


## Noradrénaline ?

ANESTHESIOLOGY 2015; 122:736-45

Co remplissage  
cristalloïdes  
2 litres

Rachianesthésie →

Bupivacaïne 11 mg  
Fentanyl 15 µg



© SH - Association SPARADRAP



Phényléphrine  
100 µg/ml

30 ml/h puis ajusté selon la PAS







Noradrénaline  
5 µg/ml

# Randomized Double-blinded Comparison of Norepinephrine and Phenylephrine for Maintenance of Blood Pressure during Spinal Anesthesia for Cesarean Delivery

Noradrénaline 5 µg/ml vs. phényléphrine 100 µg/ml

Warwick D. Ngan Kee, M.B.Ch.B., M.D., F.A.N.Z.C.A., F.H.K.A.M.,  
 Shara W. Y. Lee, B.Sc.(Hons.), M.Sc., Ph.D., Floria F. Ng, R.N., B.A.Sc.,  
 Perpetua E. Tan, B.Sc., M.Phil., Kim S. Khaw, M.B.B.S., M.D., F.R.C.A., F.H.K.A.M.



**C**

# Randomized Double-blinded Comparison of Norepinephrine and Phenylephrine for Maintenance of Blood Pressure during Spinal Anesthesia for Cesarean Delivery

Warwick D. Ngan Kee, M.B.Ch.B., M.D., F.A.N.Z.C.A., F.H.K.A.M.,  
 Shara W. Y. Lee, B.Sc.(Hons.), M.Sc., Ph.D., Floria F. Ng, R.N., B.A.Sc.,  
 Perpetua E. Tan, B.Sc., M.Phil., Kim S. Khaw, M.B.B.S., M.D., F.R.C.A., F.H.K.A.M.

**Table 2.** Neonatal Outcome

	Norepinephrine Group	Phenylephrine Group	P Value
Birth weight (kg)	3.11 [2.85–3.37]	3.19 [3.04–3.36]	0.37
Apgar score at 1 min <8	0	0	
Apgar score at 5 min <8	0	0	
Umbilical arterial blood gases			
pH	7.30 [7.28–7.33]	7.29 [7.28–7.32]	0.45
PCO <sub>2</sub> (mmHg)	50 [48–56]	52 [48–56]	0.77
PO <sub>2</sub> (mmHg)	15 [13–18]	14 [11–16]	0.20
Base excess (mmol/l)	-2.0 [-3.7 to -1.0]	-2.4 [-4.2 to -0.8]	0.87
Oxygen content (ml/dl)	6.0 [4.4–7.7]	5.2 [3.8–7.0]	0.29
Umbilical venous blood gases			
pH	7.35 [7.34–7.37]	7.34 [7.32–7.36]	0.031
PCO <sub>2</sub> (mmHg)	41 [38–43]	41 [38–45]	0.69
PO <sub>2</sub> (mmHg)	27 [23–30]	26 [23–28]	0.23
Base excess (mmol/l)	-3.2 [-4.1 to -2.0]	-3.5 [-5.6 to -2.4]	0.06
Oxygen content (ml/dl)	12.7 [11.3–14.4]	11.8 [9.6–13.7]	0.047

Values are median [interquartile range] or number.

# Randomized Double-blinded Comparison of Norepinephrine and Phenylephrine for Maintenance of Blood Pressure during Spinal Anesthesia for Cesarean Delivery

Warwick D. Ngan Kee, M.B.Ch.B., M.D., F.A.N.Z.C.A., F.H.K.A.M.,  
 Shara W. Y. Lee, B.Sc.(Hons.), M.Sc., Ph.D., Floria F. Ng, R.N., B.A.Sc.,  
 Perpetua E. Tan, B.Sc., M.Phil., Kim S. Khaw, M.B.B.S., M.D., F.R.C.A., F.H.K.A.M.

**Table 2.** Neonatal Outcome

	Norepinephrine Group	Phenylephrine Group	P Value
Birth weight			0.37
Apgar score at 1 min			
Apgar score at 5 min			
Umbilical artery pH			0.45
Umbilical artery PCO <sub>2</sub> (mmHg)			0.77
Umbilical artery PO <sub>2</sub> (mmHg)			0.20
Umbilical artery Base excess (mmol/L)			0.87
Umbilical artery Oxygen saturation			0.29
Umbilical vein pH			0.031
Umbilical vein PCO <sub>2</sub> (mmHg)			0.69
Umbilical vein PO <sub>2</sub> (mmHg)			0.23
Umbilical vein Base excess (mmol/L)			0.06
Umbilical vein Oxygen saturation			0.047

**Noradrénaline aussi efficace que phényléphrine pour la prévention de l'hypotension, avec moins de bradycardies, fréquence cardiaque et débit cardiaques améliorés**

**Effet potentiellement bénéfique sur débit utéroplacentaire**

**Impacts sur paramètres néonataux à préciser**

Values are median [interquartile range] or number.

# The Effect of patient warming during Caesarean delivery on maternal and neonatal outcomes: a meta-analysis

Faut-il réchauffer nos patientes ?

P. Sultan<sup>1,\*</sup>, A. S. Habib<sup>2</sup>, Y. Cho<sup>3</sup> and B. Carvalho<sup>4</sup>

<sup>1</sup>Department of Anaesthesia, University College London Hospital, London, UK, <sup>2</sup>Department of Anesthesia, Duke University School of Medicine, Durham, NC, USA, <sup>3</sup>Pacific Alliance Medical Center, Los Angeles, CA, USA, and <sup>4</sup>Department of Anesthesia, Stanford University School of Medicine, Stanford, CA, USA




Fig 2 Forest plots of the primary outcome of maximum core temperature change.

Bénéfice maternel (confort)

Bénéfice sur les paramètres néonataux à confirmer

Réchauffement actif des patientes opérées de césarienne devrait être encouragé

# The Effect of Intrathecal Morphine Dose on Outcomes After Elective Cesarean Delivery: A Meta-Analysis

Pervez Sultan, MBChB, FRCA,\* Stephen H. Halpern, MD,† Ellile Pushpanathan, MBBS, BMedSci, FRCA,‡ Selina Patel, MBBS, FRCA,\* and Brendan Carvalho, MBBCh, FRCA§

ANESTHESIA & ANALGESIA July 2016

**11 RCT, 480 patientes**

**Dose morphine 50-100 µg vs. >100-250 µg, pas d'autre opiacé intrathécal**

## Durée analgésie




Figure 4. Forest plot for the primary outcome of duration of analgesia. Mean difference is represented in hours.

**Gain moyen de 4,5 h (1,9 – 7,1 h)**

# The Effect of Intrathecal Morphine Dose on Outcomes After Elective Cesarean Delivery: A Meta-Analysis

Pervez Sultan, MBChB, FRCA,\* Stephen H. Halpern, MD,† Ellile Pushpanathan, MBBS, BMedSci, FRCA,‡ Selina Patel, MBBS, FRCA,\* and Brendan Carvalho, MBChB, FRCA§

ANESTHESIA & ANALGESIA July 2016

**11 RCT, 480 patientes**  
**Dose morphine 50-100 µg vs. >100-250 µg, pas d'autre opiacé intrathécal**

## Durée

### morphine intrathécale > 100 µg


- allongement de la durée d'analgésie < 8 h
  - pas d'effet sur la consommation de morphine et scores de douleur
  - incidence accrue de prurits, nausées, vomissements
- faibles doses suffisantes (100 µg)**

Study or Subgroup  
1.10.1 Time  
Unlugenc (4)  
Uchiyama (9)  
Milner (42)  
Jiang (41)  
Girgin (10)  
Cohen (40)  
Abboud (39)  
Subtotal (9)  
Heterogeneity:  
Test for over  
Total (95%  
Heterogeneity:  
Test for over  
Test for subgroup differences: Not applicable


Favors low dose Favors high dose

Figure 4. Forest plot for the primary outcome of duration of analgesia. Mean difference is represented in hours.

Gain moyen de 4,5 h (1,9 – 7,1 h)



ACCPM 2016



PLoS One 2014



# A Perioperative Course of Gabapentin Does Not Produce a Clinically Meaningful Improvement in Analgesia after Cesarean Delivery

## Gabapentine

A Randomized Controlled Trial

David T. Monks, M.D., David W. Hoppe, M.D., Kristi Downey, M.Sc., Vibhuti Shah, M.D., Paul Bernstein, M.D., Jose C. A. Carvalho, M.D., Ph.D.


ANESTHESIOLOGY 2015; 123:320-6

RCT double aveugle, 197 patientes

Rachianesthésie avec morphine

Analgésie multimodale (AINS, paracétamol)

Gabapentine 600 mg (vs. Placebo) 1 h avant chirurgie puis 200 mg toutes les 8 h pendant 48 h



# A Perioperative Course of Gabapentin Does Not Produce a Clinically Meaningful Improvement in Analgesia after Cesarean Delivery

## Gabapentine

*A Randomized Controlled Trial*

David T. Monks, M.D., David W. Hoppe, M.D., Kristi Downey, M.Sc., Vibhuti Shah, M.D., Paul Bernstein, M.D., Jose C. A. Carvalho, M.D., Ph.D.

ANESTHESIOLOGY 2015; 123:320-6

**Effet cliniquement modeste sur le score de douleur et la satisfaction à 24 h**

**Pas d'effet sur**

**la consommation d'opiacés**

**la douleur chronique à 2 et 6 semaines**

**4 fois plus de sédations sévères à 24 h et moins de prurit à 48 h**

**Pas de retentissements néonataux sévères**

**Évaluation à poursuivre chez patientes à risque de douleur sévère ?**

puis 200 mg toutes les 8 h pendant 48 h



# **Analgésie du travail**

# Choix des parturientes ?


## Initial Preference for Labor Without Neuraxial Analgesia and Actual Use: Results from a National Survey in France


Laure Kpéa, RM, MPH,\*† Marie-Pierre Bonnet, MD, PhD,\*†‡ Camille Le Ray, MD, PhD,\*†§  
Caroline Prunet, MPH,\*† Anne-Sophie Ducloy-Bouthors, MD,|| and Béatrice Blondel, PhD\*†

Anesth Analg 2015;121:759–66

**Données issues de l'Enquête Nationale Périnatale de 2010**

**Analyse des patientes ayant accouchées par voie basse,  
après travail spontané**





- **Facteurs associés au choix initial d'accouchement sans APD**
  - âge < 25 ans
  - parité  $\geq 2$
  - faible niveau d'études
  - nationalité étrangère
  - femme seule
  
- **Facteurs associés au recours à l'APD malgré le choix initial**
  - **oxytocine**
  - **nulliparité**
  - âge gestationnel > 41 semaines
  - **disponibilité de l'anesthésiste**
  - charge de travail des sages-femmes

**Les raisons du changement de stratégie restent à évaluer**

**Définir une population cible pour renforcer l'information en consultation d'anesthésie / préparation à la naissance ?**



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

**Hypnose**

## **Hypnosis for pain management during labour and childbirth (Review)**

Madden K, Middleton P, Cyna AM, Matthewson M, Jones L

**2016**

**9 essais randomisés (2954 patientes)**



## Hypnosis for pain management during labour and childbirth (Review)

Madden K, Middleton P, Cyna AM, Matthewson M, Jones L

**2016**

	RR ou DM (95 % CI)	
Recours à une analgésie pharmacologique	RR : 0,73 (0,57 – 0,94)	8 études, 2916 femmes
Sentiment de faire face	DM : 0,22 (-0,14 – 0,58)	1 étude, 420 femmes
AVB spontané	RR : 1,12 (0,96 – 1,32)	6 études , 2360 femmes
Satisfaction du soulagement de la douleur	DM : 0,41 (-0,45 – 1,27)	1 étude, 72 femmes

L'hypnose ne réduit pas le recours à l'analgésie péridurale

# Patient controlled analgesia with remifentanil versus epidural analgesia in labour: randomised multicentre equivalence trial

*BMJ* 2015;350:h846 doi: 10.1136/bmj.h846 (Published 23 February 2015)

794 patientes

Measure (No of women per group)	Mean area under curve		
	Remifentanil	Epidural analgesia	Difference (95% CI)
<b>With missing AUC values imputed</b>			
Satisfaction with pain relief during active labour (687/671)	30.9	33.7	-2.8 (-6.9 to 1.3)
Satisfaction with pain relief after pain relief (447/347*)	25.6	36.1	-10.4 (-13.9 to -7.0)
Pain during active labour (687/671)	30.9	27.2	3.8 (0.92 to 6.6)
Pain score after pain relief (447/347*)	26.7	20.3	6.4 (3.5 to 9.4)
<b>Missing AUC values not imputed</b>			
Satisfaction with pain relief during active labour (394/290)	27.2	37.6	-10.3 (-14.6 to -6.1)
Satisfaction with pain relief after pain relief (316/198†*)	25.5	41.3	-15.7 (-20.2 to -11.2)
Pain during active labour (438/354)	29.7	24.9	4.9 (1.7 to 8.1)
Pain score after pain relief (345/220†)	27.8	21.0	7.0 (3.3 to 10.7)

Saturation %:				
<95%	154 (37)	37 (12)	1.63 (1.46 to 1.82)	<0.001
<92%	71 (18)	14 (5)	1.52 (1.35 to 1.71)	<0.001

# A prospective observational study of maternal oxygenation during remifentanil patient-controlled analgesia use in labour\*

A. A. Messmer,<sup>1</sup> J. M. Potts<sup>2</sup> and C. E. Orlikowski<sup>3</sup>

*1 Consultant, Department of Anaesthesia, 3 Consultant, Department of Persistent Pain, Royal Hobart Hospital, Hobart, Tasmania, Australia*

*2 Statistician, The Analytical Edge, Hobart, Tasmania, Australia*

Anaesthesia 2016, 71, 171-176

Désaturation  
(SpO<sub>2</sub> < 90 %)  
chez **70 %** des  
patientes

	All	Supplementary oxygen	Room air	
Duration of recordings; h	148.2	93 (63%)	55.2 (37%)	
Number of desaturation episodes	176	88 (50%)	88 (50%)	
Number of episodes per hour	1.2	0.9	1.6	<b>P &lt; 0,05</b>
Lowest S <sub>p</sub> O <sub>2</sub> in each episode; %	87 (85-89 [68-89])	87 (85-89 [68-89])	86 (85-88 [73-89])	
Duration; s	16 (8-24 [8-104])	8 (8-16 [8-104])	16 (8-24 [8-72])	
Time spent with S <sub>p</sub> O <sub>2</sub> < 90%; min.h <sup>-1</sup>	0.35	0.25	0.5	

# A prospective observational study of maternal oxygenation during remifentanil patient-controlled analgesia use in labour\*

A. A. Messmer,<sup>1</sup> J. M. Potts<sup>2</sup> and C. E. Orlikowski<sup>3</sup>

*1 Consultant, Department of Anaesthesia, 3 Consultant, Department of Persistent Pain, Royal Hobart Hospital, Hobart, Tasmania, Australia*

*2 Statistician, The Analytical Edge, Hobart, Tasmania, Australia*

Anaesthesia 2016, 71, 171-176

Désaturation  
(SpO<sub>2</sub> < 90 %)  
chez **70 %** des  
patientes

**Analgésie par PCA rémifentanil moins efficace que l'APD**  
**Surveillance nécessaire tout le long du travail**  
**Oxygène ne réduit pas la gravité des épisodes hypoxiques**

**< 0,05**

	All	Supplementary oxygen	Room air
per hour			
Lowest S <sub>p</sub> O <sub>2</sub> in each episode; %	87 (85-89 [68-89])	87 (85-89 [68-89])	86 (85-88 [73-89])
Duration; s	16 (8-24 [8-104])	8 (8-16 [8-104])	16 (8-24 [8-72])
Time spent with S <sub>p</sub> O <sub>2</sub> < 90%; min.h <sup>-1</sup>	0.35	0.25	0.5

# Labor Analgesia and Cesarean Delivery

## An Individual Patient Meta-analysis of Nulliparous Women

Anesthesiology 2004; 100:142-8

**Table 3. Labor Events in 2,703 Nulliparous Women Randomized to Epidural or Intravenous Meperidine Analgesia Using Intent-to-treat Analysis**

Labor Event	Epidural Analgesia (n = 1,339)	Intravenous Meperidine Analgesia (n = 1,364)	P Value
Labor duration, first stage,* h	8.1 ± 5	7.5 ± 5	0.011
Labor duration, second stage,† min	60 ± 56	47 ± 57	<0.001
Oxytocin after analgesia	641 (48)	546 (40)	<0.001
Fever ≥ 38°C	309 (23)	94 (7)	<0.001

Data are presented as n (%) or mean ± SD.

\* First stage-initiation of analgesia to complete cervical dilation. † Second stage-complete cervical dilation to delivery.

**Table 4. Method of Delivery in 2,703 Nulliparous Women Randomized to Epidural or Intravenous Meperidine Analgesia Using Intent-to-treat Analysis**

Method of Delivery	Epidural Analgesia (n = 1,339)	Intravenous Meperidine Analgesia (n = 1,364)	P Value
Spontaneous vaginal	1,027 (77)	1,122 (82)	<0.001
Forceps	172 (13)	101 (7)	<0.001
Cesarean	140 (10.5)	141 (10.3)	0.920
Dystocia	109 (8.1)	123 (9.0)	0.091
Nonreassuring FHR	32 (2.4)	18 (1.3)	—

**Bolus manuel**



**Efficace**  
**Personnel impliqué**  
**Effets on/off**

**Perfusion continue**



**Bolus de complément nécessaires**  
**Blocs moteurs**




**PCEA**




**Réduction de la consommation d'AL**  
**Moins de bolus de complément**  
**Moins de blocs moteurs**  
**Satisfaction des patients**  
**Débit continu associé**

**PCEA + débit continu**



**PIEB**




# Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Labor Analgesia: The Effects on Maternal Motor Function and Labor Outcome. A Randomized Double-Blind Study in Nulliparous Women

Giorgio Capogna, MD, Michela Camorcia, MD, Silvia Stirparo, MD, and Alessio Farcomeni, PhD

**PIEB**

*Anesth Analg 2011*



**20 % extraction instrumentale si débit continu vs. 7 % si PIEB  
OR = 2,9 (1,1 – 7,9)**

*Capogna et coll. Anesth Analg 2011*


# Programmed intermittent epidural boluses for maintenance of labor analgesia: an impact study

**PIEB**

C.P. McKenzie, B. Cobb, E.T. Riley, B. Carvalho

Department of Anesthesia, Stanford University School of Medicine, Stanford, CA, USA

International Journal of Obstetric Anesthesia (2016)



**Fig. 2** Proportion of patients requiring manual, clinician-administered rescue boluses during labor analgesia receiving either CEI or PIEB. \* $P=0.012$

**709 patientes**

**PIEB vs. débit continu (+ PCEA)**

-moins de recours aux boli complémentaires

↳ **charge de travail**

-moins de péridurales latéralisées

-efficacité analgésique comparable

**Pas de différence sur taux d'extraction instrumentale**


# Programmed intermittent epidural boluses for maintenance of labor analgesia: an impact study

**PIEB**

C.P. McKenzie, B. Cobb, E.T. Riley, B. Carvalho

Department of Anesthesia, Stanford University School of Medicine, Stanford, CA, USA

International Journal of Obstetric Anesthesia (2016)




**709 patientes**

**PIEB vs. débit continu (+ PCEA)**

**Intérêt mode PIEB sur la réduction du risque d'extraction instrumentale reste à confirmer**

**Étude PrimiAL**



-efficacité analgésique comparable

**Pas de différence sur taux d'extraction instrumentale**

**Fig. 2** Proportion of patients requiring manual, clinician-administered rescue boluses during labor analgesia receiving either CEI or PIEB. \* $P=0.012$

# **Thromboprophylaxie**

**Evolution de la mortalité maternelle par causes, effectifs, % et taux pour 100 000 NV, France entière de 2001-03 à 2007-09**

Causes de décès	2001-2003			2004-2006			2007-2009 <sup>1</sup>		
	n	%	Taux	n	%	Taux	n	%	Taux
<b>Directes</b>	167	66,8	7,0	145	68,1	6,0	133	60,5	5,3
Hémorragies	61	24,4	2,6	55	25,8	2,3	42	19,1	1,6
Embolies amniotiques	23	9,2	1,0	34	16	1,4	19	8,6	0,8
Thrombo-embolies veineuses	26	10,4	1,1	20	9,4	0,8	28	12,7	1,1
Hypertension artérielle	29	11,6	1,2	17	8	0,6	22	10,0	0,9
Infections	12	4,8	0,5	7	3,3	0,3	6	2,7	0,2
Complications d'anesthésie	4	1,6	0,02	3	1,4	0,1	2	0,9	0,1
Autres directes	12	4,8	0,5	9	4,2	0,4	14	6,4	0,6
<b>Indirectes</b>	72	28,8	3,0	57	26,8	2,3	78	35,5	3,2
Maladies cardiaques	15	6,0	0,6	20	9,4	0,8	29	13,2	1,2
Accident vasculaire cérébral	27	10,8	1,1	16	7,5	0,7	19	8,6	0,8
Autres	30	12,0	1,2	21	9,9	0,9	30	13,6	1,3
<b>Causes inconnues</b>	11	4,0	0,5	11	5,1	0,5	9	4,1	0,4
<b>Toutes</b>	250	100,0	10,4	213	100,0	8,7	220	100,0	8,9

**PRATIQUE CLINIQUE**

**Prévention de la maladie thromboembolique  
veineuse périopératoire et obstétricale**

Recommandations pour la pratique clinique.

Texte court 2005

Société française d'anesthésie et de réanimation



Royal College of  
Obstetricians &  
Gynaecologists

Reducing the Risk of  
Venous Thromboembolism during  
Pregnancy and the Puerperium

Green-top Guideline No. 37a  
April 2015

**Recommandations  
pour la pratique clinique**

**Post-partum**

Élaborées par le Collège national des gynécologues  
et obstétriciens français

**2015**

# Recommandations après césarienne

	SFAR 2005	RCOG 2015
Césarienne programmée isolée	BAT seul	BAT seul
C. Programmée + 1 facteur mineur	BAT seul	Au moins 10 jours
C. Programmée + 2 facteurs mineurs	6-8 semaines	Au moins 6 semaines
C. Urgente isolée	1 à 6-8 semaines	Au moins 10 jours
C. Urgente + 1 facteur mineur	6-8 semaines	Au moins 10 jours
Haut risque	6-8 semaines	Au moins 6 semaines

# Recommandations après césarienne

	SFAR 2005	RCOG 2015	CNGOF 2015
Césarienne programmée isolée	BAT seul	BAT seul	BAT seul
C. Programmée + 1 facteur mineur	BAT seul	Au moins 10 jours	BAT seul
C. Programmée + 2 facteurs mineurs	6-8 semaines	Au moins 6 semaines	7-14 jours
C. Urgente isolée	1 à 6-8 semaines	Au moins 10 jours	BAT seul
C. Urgente + 1 facteur mineur	6-8 semaines	Au moins 10 jours	7-14 jours
Haut risque	6-8 semaines	Au moins 6 semaines	6 semaines

# Recommandations après césarienne

**Thrombo-embolie = 2<sup>e</sup> cause de mortalité maternelle directe en France**

**Nouvelles recommandations britanniques / CNGOF**

**Évaluation du risque de MTEV en début de grossesse, réajusté en cours de grossesse et en post-partum**

**Nécessité d'appropriation des recommandations en salle d'accouchement**

- Bas de contention avec lever précoce
- LOVENOX .....mL/j en sous cutané pendant .....semaine(s) à partir de .....H  
(≥ 6 H après rachianesthésie ou ablation du cathéter péridural)
- NGP à J1 puis plaquettes 2 fois par semaine (et 1 fois par semaine après 3 semaines)


<b>FDR</b>	Age > 35 ans = 1	HTA = 1 Alitement prolongé = 1	César en urgence = 3
	Poids > 80 Kg ou IMC > 30 = 1	Varices = 1 Parité > 4 = 1	Atcd MTVE avec facteur déclenchant = 3
	Pré éclampsie = 1 Césarienne prophylactique = 1	Mutation V leiden, prothrombine, Déficit AT, SAPL sans ATCD de MTEV = 3	Atcd MVTE et thrombophilie = 3 Pathologie thrombogène (MICI, Sd nephrotique) = 1
	Score 0-2 : Risque faible: BAT	Score ≥ 3 : Risque modéré : BAT +	thromboprophylaxie 6 à 8 semaines

# **Hémorragie post-partum**

# Recommandations pour la pratique clinique

## Les hémorragies du post-partum

Élaborées par le Collège national des gynécologues  
et obstétriciens français



Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF) in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR)

Loïc Sentilhes<sup>a,\*</sup>, Christophe Vayssière<sup>b,c</sup>, Catherine Deneux-Tharoux<sup>d</sup>, Antoine Guy Aya<sup>e,f</sup>, Françoise Bayoumeu<sup>g</sup>, Marie-Pierre Bonnet<sup>d,h</sup>, Rachid Djoudi<sup>i</sup>, Patricia Dolley<sup>j</sup>, Michel Dreyfus<sup>j,k</sup>, Chantal Ducroux-Schouwey<sup>l</sup>, Corinne Dupont<sup>m,n</sup>, Anne François<sup>o</sup>, Denis Gallot<sup>p,q</sup>, Jean-Baptiste Haumonté<sup>r</sup>, Cyril Huissoud<sup>m,s</sup>, Gilles Kayem<sup>t</sup>, Hawa Keita<sup>u,v</sup>, Bruno Langer<sup>w</sup>, Alexandre Mignon<sup>g</sup>, Olivier Morel<sup>x</sup>, Olivier Parant<sup>y,z,A</sup>, Jean-Pierre Pelage<sup>B</sup>, Emmanuelle Phan<sup>l</sup>, Mathias Rossignol<sup>C</sup>, Véronique Tessier<sup>D,E</sup>, Frédéric J. Mercier<sup>F,G,H</sup>, François Goffinet<sup>d,E,I</sup>

European Journal of Obstetrics & Gynecology and  
Reproductive Biology


# Fibrinogen plasma concentration before delivery is not associated with postpartum haemorrhage: a prospective observational study

O. Karlsson<sup>1,\*</sup>, A. Jeppsson<sup>2,3</sup>, M. Thornemo<sup>4</sup>, H. Lafrenz<sup>5</sup>, M. Rådström<sup>6</sup>  
and M. Hellgren<sup>7,8,9</sup>

*British Journal of Anaesthesia* 115 (1): 99–104 (2015)

1843 patientes

250 avec hémorragie > 1000 ml



**Table 3** Fibrinogen concentration and estimated blood loss in the subgroups that were independent predictors of EBL >1000 ml. Data are shown as mean (SD) (fibrinogen) or median (range) (blood loss)

Subgroup	n	Fibrinogen (g litre <sup>-1</sup> )	Estimated blood loss ml
Oxytocin stimulation	1082	5.38 (SD 0.85)	500 (85–4400)
Instrumental delivery	136	5.53 (SD 0.89)	500 (140–4400)
Caesarean section	206	5.47 (SD 0.94)	700 (160–3000)
Postpartum exploration	93	5.34 (SD 0.83)	1600 (100–4400)
Remaining population	771	5.27 (SD 0.79)	400 (70–2440)

**Fig 2** Fibrinogen concentration and estimated blood loss during delivery in 1951 women. Box-whisker plots with median (line), mean (square), 25–75% percentile. The whiskers are drawn to 1.5 of interquartile range. Dots are outliers. The green line shows estimated blood loss of 500 ml.


**Pas d'intérêt prédictif du dosage de fibrinogène à l'admission en salle**

# Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial†

A. J. Wikkelso<sup>1\*</sup>, H. M. Edwards<sup>2</sup>, A. Afshari<sup>3</sup>, J. Stensballe<sup>4</sup>, J. Langhoff-Roos<sup>5</sup>, C. Albrechtsen<sup>3</sup>, K. Ekelund<sup>3</sup>, G. Hanke<sup>3</sup>, E. L. Secher<sup>3</sup>, H. F. Sharif<sup>5</sup>, L. M. Pedersen<sup>6</sup>, A. Troelstrup<sup>6</sup>, J. Lauenborg<sup>7</sup>, A. U. Mitchell<sup>1</sup>, L. Fuhrmann<sup>1</sup>, J. Svare<sup>2</sup>, M. G. Madsen<sup>8</sup>, B. Bødker<sup>9</sup>, A. M. Møller<sup>1</sup> and FIB-PPH trial group

## Bénéfice d'une correction précoce de l'hypofibrinogénémie ?

British Journal of Anaesthesia 114 (4): 623–33 (2015)



**Fig 2** Mean fibrinogen concentrations in placebo and fibrinogen groups from baseline to 24 h after study drug administration, with whiskers indicating standard deviation. Mean difference of the fibrinogen concentration between the fibrinogen and placebo group is given below at each time point from baseline to 24 h after the study drug administration, with 95% confidence interval (CI) given in parenthesis and P-value.

# Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial<sup>†</sup>


A. J. Wikkelso<sup>1\*</sup>, H. M. Edwards<sup>2</sup>, A. Afshari<sup>3</sup>, J. Stensballe<sup>4</sup>, J. Langhoff-Roos<sup>5</sup>, C. Albrechtsen<sup>3</sup>, K. Ekelund<sup>3</sup>, G. Hanke<sup>3</sup>, E. L. Secher<sup>3</sup>, H. F. Sharif<sup>5</sup>, L. M. Pedersen<sup>6</sup>, A. Troelstrup<sup>6</sup>, J. Lauenborg<sup>7</sup>, A. U. Mitchell<sup>1</sup>, L. Fuhrmann<sup>1</sup>, J. Svare<sup>2</sup>, M. G. Madsen<sup>8</sup>, B. Bødker<sup>9</sup>, A. M. Møller<sup>1</sup> and FIB-PPH trial group

*British Journal of Anaesthesia* 114 (4): 623–33 (2015)

## Bénéfice d'une correction précoce de l'hypofibrinogénémie ?

**Table 2** Primary and secondary outcomes, intention to treat. RBC, red blood cell. Data are presented as the median [IQR] or n (%). \*One hundred and forty-eight values are missing (61%). <sup>†</sup>Mean difference with 95% confidence interval (CI; Student's t-test). <sup>‡</sup>Wilcoxon rank sum test

Outcome	Fibrinogen (n=123)	Placebo (n=121)	Relative risk (95% CI)	P-value
<b>Primary outcome</b>				
Need for RBC transfusion (during the 6 week period postpartum)	25 (20.3%)	26 (21.5%)	0.95 (0.58–1.54)	0.88
<b>Secondary outcomes</b>				
Estimated blood loss after study drug (ml)	1700 [1500–2000]	1700 [1400–2000]	66 [–78; 210] <sup>†</sup>	0.37
Need for RBC transfusion (up to 4 h after study drug)	4 (3.3%)	10 (8.3%)	0.39 (0.13–1.22)	0.11
Need for RBC transfusion (up to 24 h after study drug)	14 (11.4%)	19 (15.7%)	0.72 (0.38–1.38)	0.35
Need for RBC transfusion (up to 7 days after study drug)	25 (20.3%)	26 (21.5%)	0.95 (0.58–1.54)	0.88
Total amount of blood transfused	0 [0,0]	0 [0,0]	‡	0.83
Range [min, max]	[0,7]	[0,4]		
Severe PPH*	20 (40.0%)	24 (52.2%)	0.77 (0.49–1.19)	0.31
Death	0 (0.0%)	0 (0.0%)	–	
Haemostatic intervention	0 (0.0%)	0 (0.0%)	–	
Transfusion of ≥4 units of RBCs	8 (6.5%)	3 (2.5%)	2.62 (0.71–9.65)	0.22
Decrease in haemoglobin >40 g litre <sup>-1*</sup>	20 (40.0%)	24 (52.2%)	0.77 (0.49–1.19)	0.31
Rebleeding	2 (1.6%)	2 (1.7%)	0.98 (0.14–6.87)	1.00
Lowest haemoglobin <58 g litre <sup>-1</sup>	1 (0.8%)	5 (4.1%)	0.20 (0.02–1.66)	0.12



# Fibrinogen concentrate as a treatment for postpartum haemorrhage-induced coagulopathy: A study protocol for a randomised multicentre controlled trial. The fibrinogen in haemorrhage of DELivery (FIDEL) trial

Anne-Sophie Ducloy-Bouthors<sup>a,\*</sup>, Alexandre Mignon<sup>b</sup>, Cyril Huissoud<sup>c</sup>, Jean-Marie Grouin<sup>d</sup>, Frédéric J. Mercier<sup>e</sup>

## Bénéfice d'une correction précoce de l'hypofibrinogénémie ?

RCT multicentrique

434 patientes

Accouchement voie basse


HPP + prostaglandines (sulprostone)

### Primary outcome

Baisse de Hb  $\geq 4$  g/dl et/ou transfusion  $\geq 2$  CGR

### Autres critères

Évolution HPP, morbi-mortalité maternelle



# Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage

S. Mallaiah,<sup>1</sup> P. Barclay,<sup>1</sup> I. Harrod,<sup>2</sup> C. Chevannes<sup>1</sup> and A. Bhalla<sup>2</sup>

Anaesthesia 2015, 70, 166-175

**Hémorragie sévère**  
1500 ml + coagulopathie  
(FIBTEM 5 min < 12 mm)

avril 2011-mars 2012

Pack transfusionnel  
4 CGR, 4 PFC, 1 CPA Plq


juillet 2012-juin 2013

Transfusion 4 CGR, 1 CPA Plq  
+ fibrinogène selon ROTEM

Éventuellement  
renouvelé selon  
bilans sanguins  
(cryoprécipité)

3 g fibrinogène si FIBTEM A5 < 7 mm


Protocol for Massive Obstetric Haemorrhage,  
guided by results from ROTEM



# Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage

S. Mallaiah,<sup>1</sup> P. Barclay,<sup>1</sup> I. Harrod,<sup>2</sup> C. Chevannes<sup>1</sup> and A. Bhalla<sup>2</sup>

Anaesthesia 2015, 70, 166–175




	Shock Pack (n = 42)	Fibrinogen (n = 51)	p value
ICU admission	4 (9%)	1 (2%)	NS
TACO	4 (9%)	0	0.0367
TRALI	0	0	NS
Postpartum hysterectomy	6 (14%)	3 (6%)	NS
Death	0	0	NS


TACO, transfusion-associated circulatory overload; TRALI, transfusion-related acute lung injury.

**Analyse ROTEM → guide rapide pour l'indication de fibrinogène**  
**Gain de temps et réduction des apports transfusionnels**


# **Échographie en anesthésie obstétricale**



**membrane crico-thyroïdienne**



**TAP bloc**



**Périmédullaire**





**Accès vasculaires**



Clément Brun  
 Laurent Zieleskiewicz  
 Julien Textoris  
 Laurent Muller  
 Jean-Pierre Bellefleur  
 François Antonini  
 Maxime Turrett  
 Denis Ortega  
 Armand Vellin  
 Jean-Yves Lefrant  
 Léon Boubli  
 Florence Bretelle  
 Claude Martin  
 Marc Leone

## Prediction of fluid responsiveness in severe preeclamptic patients with oliguria

Intensive Care Med (2013) 39:593–600





**$\Delta ITV > 12\%$  lors du lever de jambe passif prédictif de la réponse au remplissage vasculaire lors de pré éclampsie sévère avec oligurie**

# Lung Ultrasound Predicts Interstitial Syndrome and Hemodynamic Profile in Parturients with Severe Preeclampsia

Laurent Zieleskiewicz, M.D., Claire Contargyris, M.D., Clément Brun, M.D., Maxime Touret, M.D., Armand Vellin, M.D., François Antonini, M.D., Laurent Muller, M.D., Ph.D., Florence Bretelle, M.D., Ph.D., Claude Martin, M.D., Marc Leone, M.D., Ph.D.

ANESTHESIOLOGY 2014



ECS > 25 prédictif de rapport E/E' > 9,5

## Lung ultrasound-guided management of acute breathlessness during pregnancy

L. Zieleskiewicz,<sup>1</sup> D. Lagier,<sup>2</sup> C. Contargyris,<sup>2</sup> A. Bourgoïn,<sup>1</sup> L. Gavage,<sup>1</sup> C. Martin<sup>3</sup> and M. Leone<sup>4</sup>

**Apprentissage simple et rapide**  
**Aide à la prise en charge de**  
**nombreuses situations cliniques**

## Nicardipine-associated pulmonary edema in a parturient: use of chest ultrasound

L. Zieleskiewicz,<sup>1</sup> V. Boustiere,<sup>1</sup> A. Bourgoïn, E. Hammad, M. Leone

# Determination of a cut-off value of antral area measured in the supine position for the fast diagnosis of an empty stomach in the parturient

*A prospective cohort study*

Lucille Jay, Laurent Zieleskiewicz, François-Pierrick Desgranges, Bérengère Cogniat, Marius Pop, Pierre Boucher, Amandine Bellon, Marc Léone, Dominique Chassard and Lionel Bouvet, for the AzuRea collaborative network




*Eur J Anaesthesiol* 2016; **33**:1–8

**2016**

## Ultrasonographic measurement of antral area for estimating gastric fluid volume in parturients

L. Zieleskiewicz<sup>1</sup>, M. C. Boghossian<sup>1</sup>, A. C. Delmas<sup>1</sup>, L. Jay<sup>2</sup>, A. Bourgoïn<sup>1</sup>, X. Carcopino<sup>3</sup>, M. Poirier<sup>1</sup>, B. Cogniat<sup>2</sup>, A. Stewart<sup>4</sup>, D. Chassard<sup>2,5</sup>, M. Leone<sup>1,6</sup> and L. Bouvet<sup>2,7,\*</sup> for the AzuRea and CAR'Echo Collaborative Networks

*British Journal of Anaesthesia*, 117 (2): 198–205 (2016)



**Aide à l'estimation du risque d'inhalation pulmonaire  
Stratégie anesthésique lors de certaines urgences (DA RU...)**

**Merci de votre attention**